Cancer therapy combining a targeted drug conjugate with light-activated illumination to selectively destroy tumor cells.
Healthcare📍 San Diego, USAFounded 2013
Current Valuation
Private
as of 2026-Q1
PRIVATE
IPO Outlookprivate
Is Rakuten Medical going public?
No. Rakuten Medical is private and has not filed to go public. There is no S-1 on file.
What is Rakuten Medical's valuation in 2026?
No confirmed valuation is on record for Rakuten Medical. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Rakuten Medical filed an S-1?
No public S-1 is on file for Rakuten Medical.
Who are Rakuten Medical's investors?
Rakuten Medical's investors include Rakuten Group, SBI Group.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Rakuten Medical develops Alluminox photoimmunotherapy — a precision cancer treatment combining an antibody-dye drug conjugate with infrared-light activation to selectively destroy tumor cells. Founded in 2013 as Aspyrian Therapeutics, rebranded Rakuten Medical in 2019 after Rakuten Group became a majority investor (Mickey Mikitani serves as Chairman & CEO). Raised an oversubscribed $100M Series F in January 2026 to advance US regulatory approval.
Company Profile
CEO
Mickey Mikitani
Founded
2013
HQ
San Diego, USA
Employees
~250
Total Raised
$600M
Last Round
Series F — $111.52M (Apr 2026) · Lead: Rakuten Group
IPO Status
private
Fundraising Status
Series F · $111.52M · 4 mo ago
privateTotal raised $600M
Secondary Market
Implied price / share
$4.6
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series F
$111.52M
Apr 2026
Rakuten Group
—
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
7
4 active · 1 recruiting
Lead phase
Phase 3
most advanced registered study
Focus areas
Head and Neck Cancer
Recurrent Head and Neck Squamous Cell Carcinoma · Metastatic Head-and-neck Squamous-cell Carcinoma
Latest trial start
2024-12-24
Name-verified against lead sponsor "Rakuten Medical, Inc." on ClinicalTrials.gov as of 2026-08-19. Verify on ClinicalTrials.gov ↗
Talent Signal
Hiring trend
● First snapshot
trend accrues with monthly sweeps
Open roles
3
via careers page
Product-build share
100%
engineering, research, product, design
Trajectory
steady
heavy product build — 100% of open roles are product-building functions (engineering/research/product) — 3 of 3 open roles are medical.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Counted from Rakuten Medical's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2026-Q1. Refreshed quarterly.